Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study

BMC Pulmonary Medicine

Research Article

Hae-Sim Park¹  Young-Joo Cho²  Jean Bousquet³  Michael Gibbs⁴  Neil Barnes⁵  Susan A Tomkins⁶  Nadeem Gul⁶  Xin Zhou⁷  Nanshan Zhong⁸  William Busse⁹ 

[1] Ajou University Medical Center, Suwon, South Korea;Ewha Womans University, School of Medicine, Seoul, South Korea;Fondation MACVIA-LR, Contre les Maladies Chroniques pour un Vieillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, University of Montpellier, Montpellier, France;INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, U1168, Paris, France;UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Paris, France;Global Respiratory Franchise, GSK House, Brentford, Middlesex, UK;Global Respiratory Franchise, GSK House, Brentford, Middlesex, UK;William Harvey Institute, Barts and the London School of Medicine and Dentistry, London, UK;Quantitative Science, Clinical Statistics, GSK, Stockley Park, Middlesex, UK;Shanghai First People’s Hospital, Shanghai, China;State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA;

关键词: Asian patients;    Asthma;    Asthma control;    Asthma treatment;    Fluticasone propionate/salmeterol;    ICS/LABA treatment;   

DOI  :  10.1186/s12890-017-0410-x

 received in 2016-09-20, accepted in 2017-04-11,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundTo analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients.MethodsA post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately.ResultsIn Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified.ConclusionsA greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups.

【 授权许可】

CC BY   
© The Author(s). 2017